ZIP1 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5115913-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA5115913 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
ZIP1
Classification
Polyclonal
Conjugate
Unconjugated
Gene
Slc39a1
Gene Alias
CGI-08; CGI-71; IRT1; mZIP1; SLC39A1; solute carrier family 39 (zinc transporter), member 1; solute carrier family 39 (zinc transporter), member 3; solute carrier family 39 member 1; Zinc transporter ZIP1; Zinc-iron-regulated transporter-like; Zip1; ZIP-1; ZIRTL; Zrt- and Irt-like protein 1; Zrt/Irt-like protein 1
Host Species
Rabbit
Purification Method
Affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
27173, 30791, 361986
Content And Storage
-20°C
Form
Liquid
Applications
Immunocytochemistry, Immunohistochemistry (Paraffin), Western Blot
Concentration
1 mg/mL
Formulation
PBS with 50% glycerol and 0.02% sodium azide
Gene Accession No.
Q9NY26, Q9QZ03
Gene Symbols
Slc39a1
Immunogen
A synthesized peptide derived from human SLC39A1(Accession Q9NY26), corresponding to amino acid residues L111-D161.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Antibody detects endogenous levels of total SLC39A1
- ZIP1, also known as ZIRTL (zinc-iron regulated transporter-like), is the first mammalian member of a family of divalent ion transporters
- Zinc is an essential ion for cells and plays significant roles in the growth, development, and differentiation
- ZIP1 expression is markedly downregulated in a number of cancerous tissues and is thought to function as a tumor suppressor gene in prostate cancer
- More recent studies have shown that overexpression of ZIP1 and concomitant increased levels of intracellular zinc in PC-3 cells cause a significant inhibition of NF-kappa-B, leading to down-regulation of the antiapoptotic protein Bcl-2, Bcl-XL, and the apoptosis inhibitor XIAP, reducing the malignant potential of prostate cancer cells in vitro and in vivo.